Clinical Trial Update: Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology [Phase 4]

View source ↗

Summary

Phase 4 study evaluating whether adding linagliptin to empagliflozin affects islet cell physiology in type 2 diabetes; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)
• Tradjenta (Linagliptin)

Snippet

Sponsor: Profil Institut für Stoffwechselforschung GmbH | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED